Skip to main content

Kezar Life Sciences (US:KZR) — Company Overview, News & Financial Data

Kezar Life Sciences logo
KZRKezar Life Sciences
Kezar Life Sciences primary media
Company profile

About Kezar Life Sciences

Kezar Life Sciences (NASDAQ:KZR) focuses on discovering and developing novel treatments for autoimmune diseases and cancer. With a passion for improving patients' lives, Kezar is dedicated to pushing the boundaries of science to create therapies that can make a real difference. Their robust pipeline includes projects aimed at tackling a variety of challenging medical conditions, highlighting their commitment to innovation and their objective to bring transformative treatments into areas of high unmet medical need. As they continue to advance their research and development efforts, Kezar Life Sciences remains steadfast in its goal to not only understand the underlying mechanisms of these diseases better but also to provide new, effective solutions for them.

Snapshot

Public USOwnership
2015Year founded
58Employees
South San Francisco, United StatesHead office
Loading Map...
Global footprint

Operations

Products and/or services of Kezar Life Sciences

  • KZR-616, a novel immunoproteasome inhibitor being explored for autoimmune diseases
  • KZR-261, a first-in-class protein secretion pathway inhibitor for solid tumor malignancies
  • Focus on oncology and immunology, developing treatments targeting protein homeostasis
  • Preclinical research on novel targets in the protein secretion and degradation pathways
  • Collaboration with global pharmaceutical companies to advance their pipeline
  • Investment in cutting-edge research technologies to enhance drug discovery and development processes

Kezar Life Sciences executive team

  • Dr. Christopher J. Kirk Ph.D.Co-Founder, CEO & Director
  • Mr. John Franklin FowlerCo-Founder & Director
  • Mr. Marc L. Belsky CPACFO & Secretary
  • Mr. Mark SchillerChief Operations Officer
  • Dr. Jack Taunton Ph.D.Co-Founder